Clinical Trial Update: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years [Phase 1]

View source ↗

Summary

A Phase 1, randomized study in healthy adults assessing safety, tolerability, and pharmacokinetics of ABS-1230 compared with placebo.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kcnt1-related Epilepsy

Drugs mentioned

• ABS-1230 (ABS-1230)

Snippet

Sponsor: Actio Biosciences, Inc. | Conditions: KCNT1-Related Epilepsy | Phase 1 | Status: RECRUITING